What are the key biochemical markers for diagnosing diabetes mellitus, and how should they be monitored in primary care?

Guideline-aligned answer with reasoning, red flags and references. Clinically reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP.

Posted: 22 August 2025Updated: 22 August 2025 Guideline-Aligned (High Confidence) Clinically Reviewed
Dr Kola Tytler MBBS CertHE MBA MRCGPClinical Lead • iatroX

Key biochemical markers for diagnosing diabetes mellitus include glycated haemoglobin (HbA1c), fasting plasma glucose, and oral glucose tolerance test (OGTT) results. HbA1c is the primary diagnostic marker, with a threshold of 48 mmol/mol (6.5%) or above indicating diabetes, 39–47 mmol/mol (5.7–6.4%) indicating high risk (prediabetes), and below 39 mmol/mol (5.7%) indicating low probability of diabetes . Fasting plasma glucose and OGTT remain important, especially in pregnancy and when HbA1c is unreliable or unavailable ,. For type 1 diabetes diagnosis, clinical features such as ketosis, rapid weight loss, and diabetes-specific autoantibodies are also important, with autoantibody testing recommended to confirm diagnosis . Serum C-peptide measurement may be used selectively to clarify diagnosis when autoantibody results are negative or uncertain .

Recommended monitoring methods in primary care focus on HbA1c measurement for ongoing glycaemic control, with targets individualized but generally aiming for HbA1c levels below 48 mmol/mol (6.5%) in type 1 diabetes and around 53 mmol/mol (7.0%) in type 2 diabetes to reduce complications ,. Self-monitoring of capillary blood glucose is routinely recommended for people on insulin or at risk of hypoglycaemia, but not routinely for all type 2 diabetes patients unless specific indications exist (e.g., pregnancy, hypoglycaemia risk) . Continuous glucose monitoring (CGM), including real-time and intermittently scanned systems, is increasingly offered to adults with type 1 diabetes based on individual preference and clinical need, improving glucose control and hypoglycaemia detection [].

In primary care, well-controlled patients with stable diabetes may be monitored with HbA1c testing every 6 months, while those with unstable control or treatment changes require more frequent monitoring []. When HbA1c is unreliable due to haemoglobinopathies or altered erythrocyte turnover, alternative markers such as fructosamine or glycated albumin can be used to estimate glycaemic control trends .

Educational content only. Always verify information and use clinical judgement.